BioXcel Therapeutics files for Chapter 11, gets $77.25M DIP financing, faces Nasdaq delisting

What happened

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company developing treatments for neurological and psychiatric disorders, filed for Chapter 11 bankruptcy protection on August 27, 2026. The company disclosed this in an 8-K filing on September 1.

On August 31, 2026, BioXcel entered into a debtor-in-possession (DIP) credit agreement with affiliates of Oaktree Capital Management and the Qatar Investment Authority. The DIP facility provides up to $77.25 million in financing, consisting of up to $19 million in new money term loans and up to $58.25 million in roll-up loans that convert existing prepetition debt into DIP obligations.

On the same day, Nasdaq notified BioXcel that its common stock would be delisted due to the bankruptcy filing. Trading will be suspended at the open of business on September 8, 2026, and Nasdaq will file a Form 25-NSE with the SEC. BioXcel said it does not intend to appeal and expects its stock to trade on the OTC Pink Limited Market afterward.

The DIP facility matures on January 27, 2027. The company says proceeds will fund working capital, administrative costs of the bankruptcy cases, and a potential sale of assets.

BioXcel's stock closed at $0.1159 on September 1, up 8.3% from the prior close, on volume of over 144 million shares—more than 45 times its average volume. The company reported annual revenue of $642,000 for the year ending December 31, 2025.

Why this matters

Chapter 11 bankruptcy is a court-supervised process that allows a company to keep operating while it reorganizes or sells its assets. This filing confirms BioXcel's financial distress after years of losses and minimal revenue.

The DIP financing is crucial: it provides the cash needed to continue operations during bankruptcy. The 13% interest rate on the loans reflects the high risk lenders are taking. The roll-up loans convert part of what BioXcel already owed into new debt, giving the lenders priority claim on the company's assets.

The delisting from Nasdaq is a major consequence of the bankruptcy. A Nasdaq listing provides visibility, liquidity, and credibility. Once delisted, shares typically move to the over-the-counter (OTC) market, where trading is thinner and prices can be more volatile. The company itself warns that this could further depress the stock price.

The company's revenue of $642,000 is tiny for a public biotech, illustrating that BioXcel was spending far more than it earned. The stock's jump on September 1 may reflect speculative trading in advance of the delisting, not a change in the company's fundamental situation.

What this means

An 8-K is a 'current report' that companies must file with the SEC to announce major events shareholders should know about. This 8-K covers two items: Item 2.03 (creation of a direct financial obligation) and Item 3.01 (delisting notice).

The DIP facility is a type of financing specifically designed for companies in bankruptcy. The term 'debtor-in-possession' means the company (the debtor) keeps control of its assets while under court protection. The lenders—here, Oaktree and Qatar Investment Authority—provide new money in exchange for a super-priority claim, meaning they get paid first if the company is liquidated.

The facility has two parts: New Money Loans ($19 million) are fresh cash, while Roll-Up Loans ($58.25 million) convert old debt into new debt, giving those lenders the same priority as new lenders. The 13% annual interest is very high relative to typical corporate borrowing rates, reflecting the risk.

The Form 25-NSE that Nasdaq will file is the official paperwork to remove a security from an exchange. It is different from a delisting notice: the notice is a warning, the Form 25 is the action. After that, shares trade on the pink sheets, which is a less regulated market with less transparency and lower liquidity.

For shareholders, the key points are: the company is in bankruptcy, its stock will soon be delisted from Nasdaq, and there is no guarantee the stock will continue to trade at all on the OTC market. The outcome of the bankruptcy—whether through a reorganization or a sale—remains uncertain and depends on court decisions and the company's ability to find a buyer or plan.